FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL.

Major ophthalmic events in the first quarter of 2026 included treatments for presbyopia, age-related macular degeneration ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Please provide your email address to receive an email when new articles are posted on . Patients had good visual acuity at distance, intermediate and near. Most patients said they were satisfied with ...

Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract ...

Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye surgeons a new lens option for use in ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Johnson & Johnson (NYSE:JNJ) received FDA approval for its ...

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release from Johnson & Johnson.

Add Yahoo as a preferred source to see more of our stories on Google. The approval adds to J&J’s surgical vision portfolio Johnson & Johnson (J&J) has received approval from the US Food and Drug ...

JACKSONVILLE, Fla., March 12, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) ...